PBYI

PUMA BIOTECHNOLOGY, INC. · Healthcare · Market cap $367.5M

Insiders sold $734K net in the last 90 days ·3 sellers, 0 buyers· 2 of 3 sales under Rule 10b5-1 plans· latest Form 4 filed Nov 14, 2026

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$2.1M

reported sales (SEC code S)

Unique Insiders

10

in the rolling window

Latest filing

Nov 14, 2026

MILLER MICHAEL PATRICK

PUMA BIOTECHNOLOGY, INC. (PBYI) has 19 SEC Form 4 filings (28 transaction rows) in the rolling window, disclosed by 10 distinct insiders. Most recent filing: Nov 14, 2026.

Inside the rolling window, 10 insiders at PUMA BIOTECHNOLOGY, INC. reported no open-market purchases and 17 open-market sales totaling $2.1M. The most active filer is President and CEO AUERBACH ALAN H with 3 filings. Insiders have net sold $1.8M over the trailing 6 months. The most recent open-market filing is a sale of 15,000 shares by Director MILLER MICHAEL PATRICK, dated Nov 11, 2026, worth $121K.

  • Industry:Biotechnology
  • CEO:Alan H. Auerbach
  • Employees:179
  • HQ:Los Angeles, CA, US
  • IPO:2012-04-24
Source
Sale$121KNov 14SEC ↗
Sale$46KSep 17SEC ↗
Cesano AlessandraFirst filing
Sale$567KSep 17SEC ↗
AUERBACH ALAN HFirst in 6 months
Sale$364KJul 9SEC ↗
HUNT DOUGLAS MFirst in 6 months
Sale$70KJul 9SEC ↗
NOUGUES MAXIMO FFirst in 6 months
Sale$78KJul 9SEC ↗
MOYES JAY MFirst in 4 months
Sale$159KJun 15SEC ↗
Stuglik Brian MFirst in 6 months
Sale$58KJun 15SEC ↗
Dorval AllisonFirst filing
Sale$84KJun 15SEC ↗
WILSON TROY EDWARDFirst filing
Sale$78KJun 15SEC ↗
Senderowicz AdrianFirst filing
Sale$194KJun 15SEC ↗
HUNT DOUGLAS MFirst filing
Sale$23KJan 8SEC ↗
HUNT DOUGLAS MFirst filing
Sale$29KJan 8SEC ↗
AUERBACH ALAN HFirst filing
Sale$99KJan 8SEC ↗
AUERBACH ALAN HFirst filing
Sale$106KJan 8SEC ↗
NOUGUES MAXIMO FFirst filing
Sale$27KJan 8SEC ↗
NOUGUES MAXIMO FFirst filing
Sale$38KJan 8SEC ↗
Showing 1–17 of 17
1 / 1

Congress trading PBYI 2 all-time

  • DRep. Donna ShalalaPurchase$1,001 - $15,0002019-01-23
  • DRep. Donna ShalalaOther$1,001 - $15,0002019-05-15

STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.

Frequently asked questions

How many SEC Form 4 insider filings does PBYI have?

PUMA BIOTECHNOLOGY, INC. (PBYI) has 19 SEC Form 4 filings (28 transaction rows) in the rolling 365-day window, disclosed by 10 distinct insiders. Most recent filing: Nov 14, 2026.

When was the most recent SEC Form 4 filing for PBYI?

The most recent Form 4 filing for PBYI on Tracefour is dated Nov 14, 2026.

Who is the most active insider at PBYI?

The most active SEC Form 4 filer at PBYI in the rolling window is President and CEO AUERBACH ALAN H, with 3 filings.

What is the net insider flow at PBYI over the last 6 months?

Over the trailing 180 days, insiders at PBYI have net sold $1.8M based on SEC Form 4 disclosures.

What is the total insider buy and sell value at PBYI in the current window?

Inside the rolling window, insiders at PBYI bought $0 and sold $2.1M based on SEC Form 4 filings.

Can I get alerts for PBYI insider trading?

Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at PUMA BIOTECHNOLOGY, INC. (PBYI). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.

Related companies

PUMA BIOTECHNOLOGY, INC. is in the Healthcare sector.